Byotrol plc is pleased to announce its acquisition of Medimark Scientific Limited, a leading provider of biocide-based infection control products into the animal and human healthcare markets.
Medimark is a profitable and growing business which has broad sales, marketing and distribution expertise. Medimark sells infection control products used on surfaces, instruments and hands for the Animal Health, Human Health, Laboratory, Environment and Retail markets. Whilst predominantly operating in the UK, Medimark export products to the Middle East human healthcare sector. The Company is based in Sevenoaks, Kent, has 14 employees and is ISO9001 quality registered with supporting registration under the Medical Device Directive.
There is an existing and long-standing relationship already in place between the two companies, as Byotrol is currently a supplier of skin care products to Medimark. Alcohol-free hand sanitisers are sold into the UK veterinary market under Medimark’s Esense+ brand and powered by Byotrol’s patented technology.
Whilst the acquisition is unlikely to alter the day-to-day running of both businesses for an agreed period of 2 years, there are numerous advantages for both teams to work together on technical projects and sales initiatives in the future. Byotrol benefit from a large Technical Team with capabilities in both formulation chemistry and microbiology, which Medimark will now have access to. The acquisition immediately provides Byotrol with greater scale than could be achieved through current rates of organic growth. The combination of the two businesses will greatly accelerate Byotrol’s growth profile whilst significantly reducing the execution risk from purely organic expansion.
Commenting on the acquisition, John Langlands, Chairman of Byotrol, said, “We are delighted to have concluded the acquisition of Medimark and we welcome its directors, employees, customers and stakeholders to Byotrol. The fit between the two companies is remarkably strong with Medimark’s excellent sales and marketing capabilities which dovetail perfectly with our technical expertise. We also see more opportunities to take the combined group’s infection control products into consumer markets. Our enlarged operations will now be offering cutting-edge infection control products to more customers in our jointly-targeted markets with improved propositions. We have a strong balance sheet and are confident that the combination of the two companies will bring Byotrol to critical mass with the resources to deliver sustained growth and profitability.”
Rick Hayman, Managing Director of Medimark, added, “Joining forces with Byotrol is a very exciting step forward for the Medimark team, enabling us to take our business to a new level. With their technical expertise and commercial and sales experience skills, we see the two companies as an excellent fit. We very much look forward to pursuing the market opportunities together with the Byotrol team.”